150 related articles for article (PubMed ID: 37872454)
21. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G; Bardou VJ; Clark GM; Elledge RM
Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
[TBL] [Abstract][Full Text] [Related]
22. Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.
Stecklein SR; Shen X; Mitchell MP
Clin Breast Cancer; 2016 Aug; 16(4):319-26. PubMed ID: 26943990
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis.
Weiser R; Polychronopoulou E; Hatch SS; Haque W; Ghani HA; He J; Kuo YF; Gradishar WJ; Klimberg VS
Cancer; 2022 May; 128(9):1738-1747. PubMed ID: 35137951
[TBL] [Abstract][Full Text] [Related]
24. Do non-classic invasive lobular carcinomas derive a benefit from neoadjuvant chemotherapy?
Mamtani A; Grabenstetter A; Sevilimedu V; Morrow M; Gemignani ML
Breast Cancer Res Treat; 2023 Jan; 197(2):417-423. PubMed ID: 36394689
[TBL] [Abstract][Full Text] [Related]
25. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
Rothschild HT; Clelland EN; Abel MK; Chien AJ; Shui AM; Esserman L; Khan SA; Mukhtar RA
Breast Cancer Res Treat; 2024 Jan; 203(2):245-256. PubMed ID: 37833450
[TBL] [Abstract][Full Text] [Related]
26. Re-excision rates of invasive ductal carcinoma with lobular features compared with invasive ductal carcinomas and invasive lobular carcinomas of the breast.
Arps DP; Jorns JM; Zhao L; Bensenhaver J; Kleer CG; Pang JC
Ann Surg Oncol; 2014 Dec; 21(13):4152-8. PubMed ID: 24980090
[TBL] [Abstract][Full Text] [Related]
27. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
28. Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort Study.
Tan RYC; Ong WS; Lee KH; Park S; Iqbal J; Park YH; Lee JE; Yu JH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Koh J; Han W; Im SA; Tan VKM; Phyu N; Wong FY; Tan PH; Yap YS
J Natl Compr Canc Netw; 2024 May; 22(2D):. PubMed ID: 38744306
[TBL] [Abstract][Full Text] [Related]
29. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
31. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period.
Fortunato L; Mascaro A; Poccia I; Andrich R; Amini M; Costarelli L; Cortese G; Farina M; Vitelli C
Ann Surg Oncol; 2012 Apr; 19(4):1107-14. PubMed ID: 21913022
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
33. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-A systematic review and meta-analysis.
O'Connor DJ; Davey MG; Barkley LR; Kerin MJ
Breast; 2022 Feb; 61():1-10. PubMed ID: 34864494
[TBL] [Abstract][Full Text] [Related]
34. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
[TBL] [Abstract][Full Text] [Related]
35. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology.
Moran MS; Yang Q; Haffty BG
Breast J; 2009; 15(6):571-8. PubMed ID: 19995377
[TBL] [Abstract][Full Text] [Related]
36. Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma.
Yoon TI; Jeong J; Lee S; Ryu JM; Lee YJ; Lee JY; Hwang KT; Kim H; Kim S; Lee SB; Ko BS; Lee JW; Son BH; Metzger O; Kim HJ
JAMA Netw Open; 2023 Nov; 6(11):e2342270. PubMed ID: 37938845
[TBL] [Abstract][Full Text] [Related]
37. Invasive lobular carcinoma of the breast: local recurrence after breast-conserving therapy by subtype approximation and surgical margin.
Braunstein LZ; Brock JE; Chen YH; Truong L; Russo AL; Arvold ND; Harris JR
Breast Cancer Res Treat; 2015 Jan; 149(2):555-64. PubMed ID: 25604797
[TBL] [Abstract][Full Text] [Related]
38. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer.
Göker M; Denys H; Hendrix A; De Wever O; Van de Vijver K; Braems G
Breast Cancer Res; 2023 Nov; 25(1):146. PubMed ID: 37993928
[TBL] [Abstract][Full Text] [Related]
39. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers.
Bharat A; Gao F; Margenthaler JA
Am J Surg; 2009 Oct; 198(4):516-9. PubMed ID: 19800459
[TBL] [Abstract][Full Text] [Related]
40. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
Tubiana-Hulin M; Stevens D; Lasry S; Guinebretière JM; Bouita L; Cohen-Solal C; Cherel P; Rouëssé J
Ann Oncol; 2006 Aug; 17(8):1228-33. PubMed ID: 16740599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
